{"analyses":[{"ciLowerLimit":"0.332","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.761","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.503"}],"classes":[{"categories":[{"measurements":[{"comment":"The median and the 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The upper limit of the 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"29.7","upperLimit":"NA","value":"41.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"description":"DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.","id":"OG000","title":"Atezolizumab"},{"description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.","id":"OG001","title":"Best Supportive Care (BSC)"}],"paramType":"MEDIAN","populationDescription":"PD-L1 subpopulation, defined as ≥50% TC expression by the SP263 IHC assay, included Stage II-IIIA population with valid PD-L1 SP263 measurement at baseline. Stage II-IIIA population included all randomized participants with extent of disease as either Stage II or Stage III, \\& is a subset of ITT population. Randomized ITT population included all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether the participant received the assigned treatment.","reportingStatus":"POSTED","timeFrame":"Up to 95 months","title":"DFS in the PD-L1 (SP263 ≥ 50% TC) Subpopulation Within the Stage II-IIIA Population","type":"SECONDARY","unitOfMeasure":"months"}